Infutraze

Medicinal product

(Invented) name

Infutraze

Active substance (s)

Cinko chloridas/Vario chloridas dihidratas/Mangano chloridas tetrahidratas/Natrio selenitas/Kalio jodidas

Strength

1042 µg/107,4 µg/3,6 µg/15,33 µg/2,567 µg/ml

Pharmaceutical form

koncentratas infuziniam tirpalui

Route (s) of administration

leisti į veną

Legal status for supply

Receptinis

Narrow therapeutic index (NTI)

ATC code (s)

B05XA31, Electrolytes in combination with other drugs

Marketing authorisation holder

Fresenius Kabi AB, Švedija

Date of authorisation

2023-06-21

Date of renewal

Documents

Stage

Registruotas

Controlled?

Controlled substance type

Legal basis

10a

Procedure number

SE/H/2192/001/DC

Marketing authorisation procedure

Decentralizuota procedūra

Qualitative and quantitative composition

1 ml koncentrato yra:	1 ml
Cinko chloridas	1042 µg
Vario chloridas dihidratas	107,4 µg
Mangano chloridas tetrahidratas	3,6 µg
Natrio selenitas	15,33 µg
Kalio jodidas	2,567 µg

Packages

PAKID	NPAKID	NPAKID-7	Pack type	Pack size	Type of packaging	Proposed dispensing/classification	Marketing authorisation no.	Supply status	From	To	Package is in foreign language	From	To	Mock-up
111164	97275	1097275	ampulė	10 ml N20		Receptinis	LT/1/23/5193/001	Tiekiama	-	-	No	-	-	Download

Stadijos

Data	Stadija
2023-06-21	Registruotas